Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Long-Term Investments (2017 - 2023)

Historic Long-Term Investments for vTv Therapeutics (VTVT) over the last 7 years, with Q3 2023 value amounting to $4.4 million.

  • vTv Therapeutics' Long-Term Investments fell 2895.55% to $4.4 million in Q3 2023 from the same period last year, while for Sep 2023 it was $4.4 million, marking a year-over-year decrease of 2895.55%. This contributed to the annual value of $5.6 million for FY2022, which is 3908.21% down from last year.
  • vTv Therapeutics' Long-Term Investments amounted to $4.4 million in Q3 2023, which was down 2895.55% from $8.0 million recorded in Q2 2023.
  • vTv Therapeutics' Long-Term Investments' 5-year high stood at $9.6 million during Q2 2021, with a 5-year trough of $2.5 million in Q1 2019.
  • Over the past 5 years, vTv Therapeutics' median Long-Term Investments value was $5.8 million (recorded in 2022), while the average stood at $5.4 million.
  • As far as peak fluctuations go, vTv Therapeutics' Long-Term Investments surged by 28798.39% in 2021, and later crashed by 4001.25% in 2022.
  • vTv Therapeutics' Long-Term Investments (Quarter) stood at $2.5 million in 2019, then soared by 171.17% to $6.7 million in 2020, then surged by 36.4% to $9.2 million in 2021, then tumbled by 39.08% to $5.6 million in 2022, then dropped by 21.49% to $4.4 million in 2023.
  • Its Long-Term Investments was $4.4 million in Q3 2023, compared to $8.0 million in Q2 2023 and $7.7 million in Q1 2023.